NCT03206047: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 1363 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03206047 |
|---|---|
| Title | A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 8, 2017 |
| Completion date | Nov. 10, 2020 |
| Required reporting date | Nov. 10, 2021, midnight |
| Actual reporting date | Aug. 4, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1363 |